Repotrectinib is a tyrosine kinase inhibitor compound used as a pharmaceutical raw material. It is designed for the manufacturing of therapies targeting ROS1-positive non-small cell lung cancer.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1802220-02-5
Selitrectinib
pharmaceutical raw material
IDRX-42
pharmaceutical raw material
Crenolanib
pharmaceutical raw material
Neratinib
pharmaceutical raw material
Ferric pyrophosphate citrate
pharmaceutical raw material
Milvexian
pharmaceutical raw material
Filgotinib maleate
pharmaceutical raw material
Clazosentan
pharmaceutical raw material
(3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
FIKPXCOQUIZNHB-WDEREUQCSA-N
C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C